Giao dịch Verona Pharma PLC - VRNA CFD

Verona Pharma PLC (NASDAQ: VRNA) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Its lead candidate, ensifentrine, is designed to improve lung function and reduce symptoms for patients with chronic respiratory conditions. By combining breakthrough science with a patient-centric approach, Verona Pharma aims to bring next-generation treatments to the global respiratory market.